Chan T Y, Tang C H, Critchley J A
Department of Clinical Pharmacology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT.
Postgrad Med J. 1995 Apr;71(834):227-8. doi: 10.1136/pgmj.71.834.227.
The clinical features and risk of hepatotoxicity of 'Sleep-Qik' (valerian dry extract 75 mg, hyoscine hydrobromide 0.25 mg, cyproheptadine hydrochloride 2 mg) were determined in 23 patients treated in our hospital between 1988 and 1991. The main clinical problems were central nervous system depression and anticholinergic poisoning. There was no clinical evidence of acute hepatitis in the 23 patients after taking an average of 2.5 g of valerian (range 0.5 to 12 g). There was no evidence of subclinical liver damage in 12 patients who had routine liver function tests performed approximately 6-12 hours after ingestion. Delayed onset of severe liver damage was excluded in 10 patients in whom a telephone follow-up was possible. However, subclinical liver dysfunction in the acute stage (onset after 12-24 hours) and in the intervening period after discharge from hospital could not be excluded. To establish the risk of hepatotoxicity in long-term users and in those taking an overdosage of valerian, a much larger study of longer duration with serial liver function tests is clearly needed.
1988年至1991年间,我们医院对23例使用“Sleep-Qik”(缬草干提取物75毫克、氢溴酸东莨菪碱0.25毫克、盐酸赛庚啶2毫克)的患者进行了肝毒性临床特征及风险测定。主要临床问题为中枢神经系统抑制和抗胆碱能中毒。23例患者平均服用2.5克缬草(范围为0.5至12克)后,无急性肝炎的临床证据。12例在服药后约6 - 12小时进行常规肝功能检查的患者,无亚临床肝损伤证据。10例可进行电话随访的患者排除了严重肝损伤延迟发作的情况。然而,不能排除急性期(12 - 24小时后发作)及出院后中间期的亚临床肝功能障碍。显然,为确定长期使用者及缬草过量服用者的肝毒性风险,需要进行一项持续时间更长、有系列肝功能检查的更大规模研究。